An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2019
Price : $35 *
At a glance
- Drugs ATI 502 (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 08 Aug 2019 According to an Aclaris Therapeutics media release, If the 12-month data from this trial are positive, the company intends to seek a strategic partner to further develop ATI-502 for this indication.
- 17 Jun 2019 According to an Aclaris Therapeutics media release, the 12-month results from this trial are expected by year end 2019.
- 17 Jun 2019 According to an Aclaris Therapeutics media release, Dr. Janet Roberts of Northwest Dermatology Institute, Portland, Oregon, is a principal investigator in the clinical trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History